Clinical Testing News and Research

RSS

Nelfinavir inhibits growth of HER2-positive tumors

The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute.

6 Oct 2012

Synthetic hybrid molecules more effectively tackle chemo-resistant cancers

When Linda Tuttle was diagnosed with breast cancer, she never imagined her experience would inspire her colleagues to design new treatments to tackle the disease.

3 Oct 2012

Combination of two neuroprotective therapies shows promise against Alzheimer's

The combination of two neuroprotective therapies, voluntary physical exercise, and the daily intake of melatonin has been shown to have a synergistic effect against brain deterioration in rodents with three different mutations of Alzheimer's disease.

27 Sep 2012

New optical imaging technology could aid in breast cancer diagnosis and treatment

New optical imaging technology developed at Tufts University School of Engineering could give doctors new ways to both identify breast cancer and monitor individual patients' response to initial treatment of the disease.

27 Sep 2012

OncoMed announces data from demcizumab preclinical study on pancreatic cancer

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer, today announced the online publication in Clinical Cancer Research of preclinical data demonstrating the potent anti-cancer activity of anti-DLL4 (demcizumab) in patient-derived pancreatic tumor models.

7 Sep 2012

Hopes dashed for ginkgo biloba in Alzheimer’s disease

The GuidAge trial of ginkgo biloba extract in people with evidence of memory problems confirms that the treatment does not reduce their risk for progression to Alzheimer’s disease.

6 Sep 2012

Alzheimer’s disease is not prevented by ginkgo biloba

Ginkgo biloba extract does not significantly reduce the likelihood of diagnosis of Alzheimer’s disease in older people, according to the results of the largest ever Alzheimer’s prevention study in Europe, published in The Lancet Neurology.

6 Sep 2012

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.

5 Sep 2012

Israel's Ministry of Health approves Medgenics’ INFRADURE Phase I/II clinical trials for hepatitis C

Medgenics, Inc., the developer of Biopump, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announced that Israel's Ministry of Health (MOH) has approved two Phase I/II clinical trials to assess the safety and efficacy of INFRADURE in patients with hepatitis C.

30 Aug 2012

Allegro Diagnostics announces results from BronchoGen genomic test trial on lung cancer

Allegro Diagnostics today announced that results from its AEGIS (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trials, to determine the accuracy of the BronchoGen genomic test, have been accepted for an oral presentation during the late-breaking abstract session at CHEST 2012 on Tuesday, October 23, 2012 at 4:30 p.m. The abstract will also be published in a supplement of the October 2012 issue of CHEST.

28 Aug 2012

Pristine Solutions acquires Eaton Scientific Systems

Pristine Solutions, Inc. is pleased to announce that the Company has completed the acquisition of Eaton Scientific Systems, Ltd., a biomedical product development company focused on women's health solutions.

27 Aug 2012

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Combining the recently approved BRAF inhibitor, Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and survival in an animal model, researchers at UCLA's Jonsson Comprehensive Cancer Center have shown.

16 Aug 2012

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.

8 Aug 2012

Drug molecules designed for influenza may be adapted to treat other viruses

St. Jude Children's Research Hospital study shows how compounds blocking an enzyme universal to all influenza viruses may allow development of new antiviral drugs that also avoid the problem of drug resistance

3 Aug 2012

Potential new drug to treat common inherited kidney disease

Scientists at UC Santa Barbara have demonstrated in the laboratory that a new drug is effective in treating a very common kidney disease -- although it will be a few years before it becomes available for clinical testing. The findings resulted from a collaboration between UCSB and a biotech firm based in Indiana. The study is published in this week's Journal of the American Society of Nephrology.

3 Aug 2012

CAP publishes revised version of molecular pathology checklist with dedicated section on NGS

The College of American Pathologists (CAP) published a revised version of its molecular pathology checklist with a dedicated section on next generation sequencing (NGS) as part of the new edition of the CAP Laboratory Accreditation Program checklists released July 31, 2012.

2 Aug 2012

ATP1A3 gene mutations responsible for alternating hemiplegia of childhood

Alternating hemiplegia of childhood (AHC) is a rare disorder that usually begins in infancy, with intermittent episodes of paralysis and stiffness, first affecting one side of the body, then the other. Symptoms mysteriously appear and disappear, again and again, and affected children often experience dozens of episodes per week. As they get older, children fall progressively behind their peers in both intellectual abilities and motor skills, and more than half develop epilepsy.

31 Jul 2012

ImmunoGen announces start of IMGN853 Phase I trial for ovarian cancer, other solid tumors

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN853 product candidate.

11 Jul 2012

Anti-cancer activity of HuCAL antibody revealed by new data from OncoMed

MorphoSys AG's (FSE: MOR; Prime Standard Segment, TecDAX) partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of the United States of America (PNAS) has published online data demonstrating the potent anti-cancer activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical human tumor models. OMP-18R5 is currently in Phase 1 clinical testing.

5 Jul 2012